WCM Investment Management LLC Increases Position in Repligen Co. (NASDAQ:RGEN)

WCM Investment Management LLC increased its stake in shares of Repligen Co. (NASDAQ:RGEN) by 4.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 129,954 shares of the biotechnology company’s stock after buying an additional 5,248 shares during the quarter. WCM Investment Management LLC’s holdings in Repligen were worth $24,087,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale boosted its holdings in Repligen by 1.5% in the third quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock valued at $1,663,000 after purchasing an additional 159 shares during the last quarter. American Century Companies Inc. grew its holdings in Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after purchasing an additional 107,570 shares during the period. Atria Investments Inc acquired a new stake in Repligen in the third quarter valued at approximately $1,046,000. Nordea Investment Management AB grew its holdings in Repligen by 8.9% in the fourth quarter. Nordea Investment Management AB now owns 3,563 shares of the biotechnology company’s stock valued at $646,000 after purchasing an additional 291 shares during the period. Finally, QRG Capital Management Inc. acquired a new stake in Repligen in the third quarter valued at approximately $444,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,597 shares of company stock valued at $5,039,532. 1.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on RGEN. Stifel Nicolaus raised their price objective on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. JPMorgan Chase & Co. raised their price objective on Repligen from $170.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, December 20th. Finally, KeyCorp raised their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $196.70.

Repligen Trading Down 2.6 %

Repligen stock traded down $4.55 during trading on Friday, reaching $171.53. 706,402 shares of the company were exchanged, compared to its average volume of 386,813. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a market capitalization of $9.58 billion, a P/E ratio of 238.24, a PEG ratio of 5.77 and a beta of 1.02. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75. The stock’s 50 day simple moving average is $192.16 and its two-hundred day simple moving average is $173.03.

Repligen (NASDAQ:RGEN) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. During the same quarter in the previous year, the business earned $0.68 earnings per share. The company’s revenue for the quarter was down 16.6% on a year-over-year basis. On average, equities research analysts expect that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.